S1764
补体血清 人
lyophilized powder
别名:
人血清补充剂
登录 查看组织和合同定价。
选择尺寸
关于此项目
Biological source:
human
Origin:
USA origin
Form:
lyophilized powder
Shipped in:
dry ice
biological source
human
form
lyophilized powder
origin
USA origin
technique(s)
cell culture | mammalian: suitable
impurities
virus, tested
shipped in
dry ice
storage temp.
−20°C
Quality Level
General description
补体血清从混合的人血浆中制备，并根据标签上指示的血清量进行冻干。
Application
人补体血清已用于：
- 培养DLD-1或SW-620细胞，以量化C5a释放
- 多重头抗体C3d结合试验
- 补体依赖性细胞毒性试验
人补体血清已用于：
- 培养DLD-1或SW-620细胞，以量化C5a释放
- 多重头抗体C3d结合试验
- 补体依赖性细胞毒性试验
补体血清的活性可通过体外溶血试验测定。
Physical form
由标签所示含量血清制成的冻干粉末
Analysis Note
溶血滴度（CH50单位/ml）通过Kabat/Mayer法测定。实际滴度见标签。
Disclaimer
仅供研究使用。本品在法国的科研应用受到监管，包括用于进口和出口活动（法国《公共卫生法典》Public Health Code Article L 1211-1 paragraph 2）。如《公共卫生法典》所述，购买者（即最终用户）需要从法国研究部(France Ministry of Research)获得进口授权。订购此产品即代表您已确认获得合法的进口授权。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
高风险级别生物产品--人源产品
此项目有
Savannah E Butler et al.
Frontiers in immunology, 11, 618685-618685 (2021-02-16)
Understanding humoral immune responses to SARS-CoV-2 infection will play a critical role in the development of vaccines and antibody-based interventions. We report systemic and mucosal antibody responses in convalescent individuals who experienced varying severity of disease. Whereas assessment of neutralization
S Nowicki et al.
Infection and immunity, 63(12), 4790-4794 (1995-12-01)
Human C1q displayed a dose-dependent protection of gonococcal cells (GC) from the bactericidal effect of newborn rat serum. All rat pups injected with C1q-preincubated GC developed bacteremia, while none of the animals injected with GC only were infected. After clearance
Anaïs Thiriard et al.
Frontiers in immunology, 14, 1107156-1107156 (2023-04-04)
To comprehensively analyze the quality of the antibody response between children with Multisystem inflammatory syndrome (MIS-C) and age-matched controls at one month after SARS-CoV-2 exposure, and infected in the same time-period. Serum from 20 MIS-C children at admission, and 14
Helen Kotanides et al.
Cancer immunology research, 8(10), 1300-1310 (2020-09-03)
The programmed cell death protein 1 receptor (PD-1) and programmed death ligand 1 (PD-L1) coinhibitory pathway suppresses T-cell-mediated immunity. We hypothesized that cotargeting of PD-1 and PD-L1 with a bispecific antibody molecule could provide an alternative therapeutic approach, with enhanced
Lisa Tomasi et al.
Open forum infectious diseases, 9(11), ofac554-ofac554 (2022-12-06)
The basis of the less severe clinical presentation of coronavirus disease 2019 (COVID-19) in children as compared with adults remains incompletely understood. Studies have suggested that a more potent boosting of immunity to endemic common cold coronaviruses (HCoVs) may protect
相关内容
Datasheet
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持